Skip to main content

Type 1 Von Willebrand Disease clinical trials at UCSF
1 research study open to eligible people

  • Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease

    open to eligible females ages 18-45

    This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with type 1 von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.

    San Francisco, California and other locations

Last updated: